07:20 AM EDT, 10/27/2025 (MT Newswires) -- Rakovina Therapeutics ( RKVTF ) Monday said it has presented new data at an international conference on cancer therapeutics (AACR-NCI-EORTC) in Boston. The company's poster presentation highlighted promising results from its AI-driven kt-5000AI drug discovery program for Ataxia telangiectasia and Rad3-related protein serine/threonine kinase (ATR) inhibitors for cancer therapy.

While multiple ATR inhibitors are in development globally, none have as yet shown "meaningful" central nervous system penetration, a statement noted. Rakovina's kt-5000AI program is advancing AI-designed ATR inhibitors with confirmed central nervous system exposure (CNS), potentially extending ATR-targeted therapy to patients with primary brain tumors and brain metastases.

"ATR is a central regulator of DNA damage repair and a validated target across multiple tumor types. Developing ATR inhibitors capable of penetrating the blood-brain-barrier could expand treatment options for patients with primary brain tumors and brain metastases, areas where few effective therapies exist," said chief scientific officer Mads Daugaard.

RKV edged up from near 52 week lows in Canada trade last Friday.